Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis

• Published in: Journal for immunotherapy of cancer 2018-03, Vol.6 (1), p.20-20, Article 20
• Main Authors: Steele, Keith E, Tan, Tze Heng, Korn, René, Dacosta, Karma, Brown, Charles, Kuziora, Michael, Zimmermann, Johannes, Laffin, Brian, Widmaier, Moritz, Rognoni, Lorenz, Cardenes, Ruben, Schneider, Katrin, Boutrin, Anmarie, Martin, Philip, Zha, Jiping, Wiestler, Tobias
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Analysis; Antibodies, Monoclonal - therapeutic use; Antineoplastic Agents, Immunological - therapeutic use; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - immunology; Biomarkers; Biopsy; Cancer; Cancer immunotherapy; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - immunology; CD8; CD8-Positive T-Lymphocytes - immunology; Colorectal cancer; Cytotoxicity; Female; Histopathology; Humans; Image analysis; Image Processing, Computer-Assisted; Immune response; Immuno-oncology; Immunohistochemistry; Immunotherapy; Laboratories; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - immunology; Lymphocytes; Lymphocytes, Tumor-Infiltrating - immunology; Male; Middle Aged; Morphology; Oncology; Patients; Prognosis; Prostate cancer; Tumor microenvironment; Tumor-infiltrating lymphocytes; Tumors; Young Adult
• ISSN: 2051-1426; 2051-1426
• DOI: 10.1186/s40425-018-0326-x

Immuno-oncology and cancer immunotherapies are areas of intense research. The numbers and locations of CD8+ tumor-infiltrating lymphocytes (TILs) are important measures of the immune response to cancer with prognostic, pharmacodynamic, and predictive potential. We describe the development, validation, and application of advanced image analysis methods to characterize multiple immunohistochemistry-derived CD8 parameters in clinical and nonclinical tumor tissues. Commercial resection tumors from nine cancer types, and paired screening/on-drug biopsies of non-small-cell lung carcinoma (NSCLC) patients enrolled in a phase 1/2 clinical trial investigating the PD-L1 antibody therapy durvalumab (NCT01693562), were immunostained for CD8. Additional NCT01693562 samples were immunostained with a CD8/PD-L1 dual immunohistochemistry assay. Whole-slide scanning was performed, tumor regions were annotated by a pathologist, and images were analyzed with customized algorithms using Definiens Developer XD software. Validation of image analysis data used cell-by-cell comparison to pathologist scoring across a range of CD8+ TIL densities of all nine cancers, relying primarily on 95% confidence in having at least moderate agreement regarding Lin concordance correlation coefficient (CCC = 0.88-0.99, CCC_lower = 0.65-0.96). We found substantial variability in CD8+ TILs between individual patients and across the nine types of human cancer. Diffuse large B-cell lymphoma had several-fold more CD8+ TILs than some other cancers. TIL densities were significantly higher in the invasive margin versus tumor center for carcinomas of head and neck, kidney and pancreas, and NSCLC; the reverse was true only for prostate cancer. In paired patient biopsies, there were significantly increased CD8+ TILs 6 weeks after onset of durvalumab therapy (mean of 365 cells/mm over baseline; P = 0.009), consistent with immune activation. Image analysis accurately enumerated CD8+ TILs in PD-L1+ regions of lung tumors using the dual assay and also measured elongate CD8+ lymphocytes which constituted a fraction of overall TILs. Validated image analysis accurately enumerates CD8+ TILs, permitting comparisons of CD8 parameters among tumor regions, individual patients, and cancer types. It also enables the more complex digital solutions needed to better understand cancer immunity, like analysis of multiplex immunohistochemistry and spatial evaluation of the various components comprising the tumor microenvironme